Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BRCA2 exon 11 deletion

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

HRD + BRCA2 mutation (7)

BRCA2 mutation + HR positive (3)

HR positive + BRCA2 mutation (3)

BRCA2 mutation + HER-2 negative (2)

HR negative + BRCA2 mutation (2)

ALK rearrangement + BRCA2 F2801fs (1)

BRCA1 mutation + BRCA2 mutation + TMB-H (1)

BRCA2 deletion + ATM mutation (1)

BRCA2 mutation + AKR1C3 overexpression (1)

BRCA2 mutation + ER positive (1)

BRCA2 mutation + ER positive + PGR positive (1)

BRCA2 mutation + RB1 deletion (1)

BRCA2 mutation + TMB-H (1)

BRCA2 mutation + TMB-L (1)

HR positive + BRCA2 mutation + PALB2 mutation (1)

ER positive + BRCA2 mutation (0)

HRD + BRCA2 mutation (7)

BRCA2 mutation + HR positive (3)

HR positive + BRCA2 mutation (3)

BRCA2 mutation + HER-2 negative (2)

HR negative + BRCA2 mutation (2)

ALK rearrangement + BRCA2 F2801fs (1)

BRCA1 mutation + BRCA2 mutation + TMB-H (1)

BRCA2 deletion + ATM mutation (1)

BRCA2 mutation + AKR1C3 overexpression (1)

BRCA2 mutation + ER positive (1)

BRCA2 mutation + ER positive + PGR positive (1)

BRCA2 mutation + RB1 deletion (1)

BRCA2 mutation + TMB-H (1)

BRCA2 mutation + TMB-L (1)

HR positive + BRCA2 mutation + PALB2 mutation (1)

ER positive + BRCA2 mutation (0)

›

BRCA2 exon 11 deletion	Cervical Cancer	BRCA2 exon 11 deletion	Cervical Cancer	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4	ABSK091 Sensitive: C4 – Case Studies ABSK091 Sensitive : C4
BRCA2 exon 11 deletion	Neuroendocrine Tumor	BRCA2 exon 11 deletion	Neuroendocrine Tumor	olaparib Resistant: C4 – Case Studies olaparib Resistant : C4	olaparib Resistant: C4 – Case Studies olaparib Resistant : C4
BRCA2 exon 11 deletion	Prostate Cancer	BRCA2 exon 11 deletion	Prostate Cancer	pembrolizumab + olaparib Resistant: C4 – Case Studies pembrolizumab + olaparib Resistant : C4	pembrolizumab + olaparib Resistant: C4 – Case Studies pembrolizumab + olaparib Resistant : C4